

Morgan Lewis



BLOCKBUSTER BIOLOGICS REVIEW 15SUE 20 Legislative and Regulatory Updates



Senator Reintroduces Biosimilar Red Tape Elimination Act to Push for Biosimilars to Become Interchangeable

- In July 2023, Senator Mike Lee (R, Utah) reintroduced a bipartisan bill "The Red Tape Elimination Act," a follow-up to his earlier submission to remove the class of biosimilars labeled as an "interchangeable biosimilar."
 - The new version of the bill would:
 - Amend the federal code to state that all biosimilars, upon approval, will be deemed interchangeable.
 - Remove the current requirement in the code that has been used to justify "switching studies."
 - Require the FDA to conduct a private briefing if they want to require a "switching study" for a particular biosimilar.

Contacts



Christopher J. Betti, Ph.D. Chicago T: +1.312.324.1449 christopher.betti@ morganlewis.com



Maria E. Doukas Chicago T: +1.312.324.1454 maria.doukas@ morganlewis.com



Kelly A. Plummer, Ph.D. Chicago T: +1.312.324.1490 kelly.plummer@ morganlewis.com



Margaret C. Harney Chicago T: +1.312.324.1727 margaret.harney@ morganlewis.com



Jennifer Patritti Cram, Ph.D. Washington, DC T: +1.202.739.5768 jennifer.patritticram@ morganlewis.com